Sign inJoin
Company / Finance

Neurocrine Biosciences, Inc.

NBIX · NASDAQ

Neurocrine reported FY2025 revenue of $2.86 billion and Q1 2026 revenue of $815 million, making the thesis about whether profitable neuroscience growth can broaden while pipeline and commercialization risk stay controlled.

FollowAdd to WatchlistAsk Question
NASDAQNBIXCoverage BootstrapNeurocrine Biosciences, Inc.
Latest ReportMay 20, 2026Neurocrine: the neuroscience cash engine still has to broaden beyond one franchiseView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Company filters1 company reports
Latest Thesis

Neurocrine: the neuroscience cash engine still has to broaden beyond one franchise

Neurocrine reported FY2025 revenue of $2.86 billion and Q1 2026 revenue of $815 million, making the thesis about whether profitable neuroscience growth can broaden while pipeline and commercialization risk stay controlled.

May 20, 2026Research reportSlides available
Read reportOpen slidesDiscussion (0)
Neurocrine Biosciences, Inc.the neuroscience cash engine still has to broaden beyond one fraMay 20, 2026
Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Sign in to continue

Recent Reports

Compact report index for this company.

View all 1 reports ->
ReportTypeUpdatedReadActions
Neurocrine: the neuroscience cash engine still has to broaden beyond one franchiseNeurocrine reported FY2025 revenue of $2.86 billion and Q1 2026 revenue of $815 million, making the thesis about whether profitable neuroscience growth can broaden while pipeline and commercialization risk stay controlled.NASDAQMay 20, 2026Research reportReadSlides